YH Finance | 2026-04-20 | Quality Score: 90/100
US stock correlation matrix and portfolio risk analysis to understand how your holdings interact with each other. We help you identify concentration risks and provide recommendations for improving portfolio diversification.
Published on April 16, 2026, this analysis assesses Vanguard Health Care Index Fund ETF Shares (VHT), a passively managed U.S. healthcare sector ETF with a neutral investment sentiment rating. Sponsored by Vanguard, the fund offers diversified exposure to U.S. healthcare equities across market capit
Key Developments
Launched in January 2004, VHT tracks the MSCI US Investable Market Health Care 25/50 Index, with total assets under management (AUM) of $16.45 billion as of April 16, 2026, making it one of the largest U.S.-focused healthcare ETFs. The fund charges an annual operating expense ratio of 0.09%, among the lowest in its category, and delivers a 12-month trailing dividend yield of 1.7%. Performance-wise, VHT has returned -3.63% year-to-date, with a 12-month trailing return of 12.49%. Its 52-week tradi
Market Impact
VHT’s strong risk-adjusted performance and low cost structure are driving growing adoption among both retail and institutional investors, putting competitive pressure on peer healthcare ETFs to reduce fee structures. For context, competing funds include the State Street Health Care Select Sector SPDR ETF (XLV), which has $38.67 billion in AUM and a 0.08% expense ratio, and the iShares Global Healthcare ETF (IXJ), with $3.68 billion in AUM and a 0.4% expense ratio. As a passive index fund, inflow
In-Depth Analysis
While VHT carries a Zacks Strong Buy rank, our neutral overall sentiment reflects balanced upside and downside risks for 2026. On the upside, the fund’s 0.67 beta means it is 33% less volatile than the broader S&P 500, offering meaningful downside protection during market corrections, while its ultra-low expense ratio delivers a ~30 basis point annual compounding advantage over the average category peer. Its broad 416-holding portfolio provides exposure to both large-cap pharma and small-cap biotech, balancing stable dividend income with long-term pipeline upside. On the downside, its 12.7% allocation to LLY creates concentrated single-stock risk, as adverse developments for LLY’s GLP-1 drug portfolio would drive disproportionate downside for the fund. The U.S. healthcare sector is currently ranked 7 out of 16 Zacks sectors, placing it in the top 44% of sector performers but indicating it is not a leading market segment for 2026. For investors, VHT is an optimal holding for long-term, moderate-risk portfolio allocations, but investors seeking global exposure should consider IXJ, while those wanting more concentrated large-cap healthcare exposure may prefer XLV. (Total word count: 762)